Fatostatin hydrobromide

Overview

Fatostatin hydrobromide (125B11 hydrobromide), a specific inhibitor of SREBP activation , impairs the activation of SREBP-1 and SREBP-2. Fatostatin hydrobromide binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin hydrobromide decreases the transcription of lipogenic genes in cells. Fatostatin hydrobromide possesses antitumor properties, and lowers hyperglycemia in ob/ob mice.

Application

Products | Products > Disease Areas > Obesity | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Digestive System Inflammation | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Fatty Acid Synthase (FASN)

Product Information

• Catalog No.: HY-14452A
• CAS No.: 298197-04-3
• Molecular Formula: C18H19BrN2S
• Molecular Weight: 375.33
• Purity: 99.52%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.08 mg/mL (5.54 mM); Clear solution
• Availability: In-stock

Source

Original product source